Color Vision Loss and Retinal Changes Correlation, and a Novel Color Test

Launched by ZHONGMOU THERAPEUTICS · Jul 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how changes in color vision relate to physical changes in the retina—the part of the eye that helps us see—in people with inherited retinal dystrophies (IRD). These are genetic eye conditions that can affect vision, including the ability to see colors. The study aims to understand how problems with color vision connect to damage in specific layers of the retina, as seen through advanced eye scans. It will also look at how different genetic mutations and a person’s age might affect the severity of color vision loss. Additionally, the study will test a new color vision test called the Moji Test, designed to measure color perception even in people who have serious central vision loss.

The trial is looking to enroll about 200 participants, including people with inherited retinal dystrophies and others without any retinal disease to serve as a comparison group. To take part, you need to be able to recognize and describe colors and follow test instructions. Those in the IRD group must have a confirmed diagnosis, while control participants should have healthy retinas and normal color vision. During the study, participants will undergo color vision testing, visual acuity checks (which measure how well you see), and detailed retinal imaging. This will help researchers better understand the connection between color vision loss and retinal changes, and evaluate the new Moji Test’s usefulness for people with advanced vision problems.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Color Perception and Communication Ability Participants must have the ability to verbally identify or describe colors and test stimuli. This requires adequate cognitive and communicative capacity to understand instructions and respond appropriately during color vision testing.
• • 2. Diagnosis of Inherited Retinal Dystrophy (IRD Group Only) Participants assigned to the IRD group must have a confirmed clinical diagnosis of an inherited retinal dystrophy
• • 3. No Evidence of Inherited Retinal Disease (Control Group Only)
• Participants in the control group must have:
• • No known history or clinical evidence of inherited retinal degeneration
• • Normal retinal health or only non-retinal ocular conditions not affecting retinal function (e.g., mild cataract, corrected refractive error)
• • Normal or expected-normal color vision
• Exclusion Criteria:
• • 1. Non retinal causes of color vision loss
• • Optic neuropathies (e.g., optic neuritis, glaucoma related optic nerve damage)
• • Cortical vision impairments affecting color perception
• • Any other neurological or optic nerve pathology causing color vision deficiency
• • 2. Psychological or cognitive conditions affecting color perception or communication
• • Severe developmental delays
• • Cognitive impairments interfering with ability to comprehend or reliably perform color vision tests
• • Psychiatric conditions that impair visual interpretation or reliable testing
• • 3. Prior treatment with potential transient effects on the retina
• • Recent retinal surgery
• • Recent drug therapy affecting retinal structure or function
• • Any acute intervention that might confound the correlation analyses due to lack of a stable baseline